A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus MERS-CoV developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate models when given intradermally in abbreviated, low-dose immunization regimen. A similar vaccine candidate was previously shown to be safe and tolerable with a three-dose intramuscular injection regimen in a recently completed human phase 1 study and is currently in expanded studies of phase 1/2a trial. New results were published today in JCI Insight.
- Read more about Low-dose Administration of MERS DNA Vaccine Candidate Induces Potent Immunity and Protects From Virus Challenge in Preclinical Models
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/low-dose-administration-of-mers-dna-vaccine-candidate-induces-potent-immunity-and-protects-from-virus-challenge-in-preclinical-models
No comments:
Post a Comment